Ang, Agnes

Sotorasib for Lung Cancers with KRAS p.G12C Mutation

Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 1,849

Diverse alterations associated with resistance to KRAS(G12C) inhibition

Zhao, Y., Murciano-Goroff, Y. R., Xue, J. Y., Ang, A., Lucas, J., Mai, T. T., Da Cruz Paula, A. F., Saiki, A. Y., Mohn, D., Achanta, P., et al. (2021) · Nature

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 479

Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy

Price, T., Ang, A., Boedigheimer, M., Kim, T. W., Li, J., Cascinu, S., Ruff, P., Satya Suresh, A., Thomas, A., Tjulandin, S., et al. (2020) · Cancer Biology & Therapy

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 33

Largest evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated non–small cell lung cancer (NSCLC) and colorectal cancer (CRC): Plasma biomarker analysis of CodeBreaK100.

Li, B. T., Velcheti, V., Price, T. J., Hong, D. S., Fakih, M., Kim, D.-W., Falchook, G. S., Delord, J.-P., Dy, G. K., Ramalingam, S. S., et al. (2022) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 27

Overall survival and exploratory subgroup analyses from the phase 2 CodeBreaK 100 trial evaluating sotorasib in pretreated KRAS p.G12C mutated non-small cell lung cancer.

Skoulidis, F., Li, B. T., Govindan, R., Dy, G. K., Shapiro, G., Bauml, J., Schuler, M. H., Addeo, A., Kato, T., Besse, B., et al. (2021) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 24

Abstract CT008: Long-term outcomes with sotorasib in pretreated KRASp.G12C-mutated NSCLC: 2-year analysis of CodeBreaK100

Dy, G. K., Govindan, R., Velcheti, V., Falchook, G. S., Italiano, A., Wolf, J., Sacher, A. G., Takahashi, T., Ramalingam, S. S., Dooms, C., et al. (2022) · Cancer Research

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 16